2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Pulmonary Embolism
1
Gastrointestinal Neoplasms
1
Interventions
Specimen Handling
641
pembrolizumab
585
Magnetic Resonance Spectroscopy
555
Carboplatin
431
Cyclophosphamide
381
Cisplatin
379
Biopsy
376
Nivolumab
315
Paclitaxel
314
Gemcitabine
308
Radiotherapy
286
Bevacizumab
235
Dexamethasone
218
fludarabine
206
Docetaxel
194
durvalumab
189
Oxaliplatin
189
venetoclax
187
Rituximab
175
Fluorouracil
175
atezolizumab
172
Pemetrexed
167
Capecitabine
164
Radiosurgery
162
Doxorubicin
162
Radiation
160
Ipilimumab
146
Lenalidomide
140
Leucovorin
138
Etoposide
134
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dalteparin
×
90 days
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled